Scientific article
English

The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients

Published inAntiviral therapy, vol. 17, no. 3, p. 541-547
Publication date2012
Abstract

Chronic hepatitis C infection is a major cause of end-stage liver disease. Therapy outcome is influenced by 25-OH vitamin D deficiency. To further address this observation, our study investigates the impact of the vitamin D receptor (NR1I1) haplotype and combined effects of plasma vitamin D levels in a well-described cohort of hepatitis C patients.

Keywords
  • Adult
  • Aged
  • Antiviral Agents/therapeutic use
  • Cohort Studies
  • Drug Therapy, Combination
  • Female
  • Genotype
  • Haplotypes/genetics
  • Hepacivirus/drug effects/genetics
  • Hepatitis C, Chronic/drug therapy/genetics/virology
  • Humans
  • Interferons/therapeutic use
  • Male
  • Middle Aged
  • Polyethylene Glycols/therapeutic use
  • Polymorphism, Genetic
  • Receptors, Calcitriol/genetics
  • Ribavirin/therapeutic use
  • Treatment Outcome
  • Vitamin D/blood
Citation (ISO format)
BAUR, Katharina et al. The vitamin D receptor gene bAt (CCA) haplotype impairs the response to pegylated-interferon/ribavirin-based therapy in chronic hepatitis C patients. In: Antiviral therapy, 2012, vol. 17, n° 3, p. 541–547. doi: 10.3851/IMP2018
Main files (1)
Article (Published version)
accessLevelRestricted
Identifiers
Journal ISSN1359-6535
685views
1downloads

Technical informations

Creation26/03/2013 14:24:00
First validation26/03/2013 14:24:00
Update14/03/2023 20:09:23
Status update14/03/2023 20:09:23
Last indexation30/10/2024 09:18:07
All rights reserved by Archive ouverte UNIGE and the University of GenevaunigeBlack